Insufficient patient accrual is a major challenge in clinical trials and can result in underpowered studies, as well as exposing study participants to toxicity and additional costs, with limited scientific benefit. Real-world data can provide external controls, but insufficient accrual affects all arms of a study, not just controls. Studies that used generative models to simulate more patients were limited in the accrual scenarios considered, replicability criteria, number of generative models, and number of clinical trials evaluated.
Researchers
-
Khaled El Emam
Senior Scientist, CHEO Research Institute Professor, Faculty of Medicine, University of Ottawa
-
Dhenuka Radhakrishnan
Scientist, CHEO Research Institute